Human cytomegalovirus, abbreviated HCMV, carries a double-stranded DNA genome of approximately 230 kilobase pairs, making it one of the larger viral genomes that replicates inside human cells. During lytic infection, when the virus actively produces new progeny, this genome is copied repeatedly and at high speed, a process that inevitably generates DNA lesions and replication-associated stress. Because HCMV does not encode a canonical set of DNA repair enzymes of its own, it must depend on the DNA damage response machinery of the host cell to keep its genome in a replicable state. How the virus directs host repair proteins specifically to its own DNA, rather than allowing them to disperse across the cellular genome, has remained a poorly understood question in virology.

The new work identifies MORC Family CW-type zinc finger 2, or MORC2, as a central player in answering that question. MORC2 is a host chromatin remodeler, an ATP-consuming enzyme that alters the packaging of DNA around histone proteins and thereby changes how accessible specific stretches of chromatin are to the proteins that act on them. The researchers found that HCMV infection induces the expression of MORC2 in infected cells, and that this induction is not incidental. When MORC2 was depleted, viral DNA replication became less efficient and the production of progeny virus dropped, indicating that the protein provides a tangible benefit to the viral life cycle.

A key observation of the study concerns the localization of MORC2 during infection. In uninfected cells, MORC2 is distributed in a pattern associated with its normal chromatin-related functions. Upon HCMV infection, however, the protein redistributes to viral replication compartments, specialized nuclear structures where viral genomes accumulate, are copied and are packaged into new virions. This relocalization places MORC2 physically at the sites where viral DNA is most vulnerable to damage and where the DNA damage response must be deployed if replication is to continue without catastrophic genome failure.

The mechanistic detail that emerges from the study is that MORC2 acts on the architecture of viral chromatin itself. Using its ATPase activity, the energy-consuming motor domain characteristic of this family of remodelers, MORC2 enhances the accessibility of viral chromatin. In practical terms, the viral genome, which is coated with nucleosomes and otherwise relatively compacted, becomes more open in the presence of active MORC2. This opening has a downstream consequence that lies at the heart of the paper: it facilitates the accumulation of gamma-H2AX, the phosphorylated form of histone variant H2AX that serves as the canonical beacon of DNA double-strand breaks and the organizing signal for the cellular damage response.

Gamma-H2AX is more than a passive marker. Its accumulation over damaged DNA creates a platform onto which repair factors are recruited, forming foci that coordinate sensing, signaling and repair of lesions. The researchers showed that MORC2-dependent chromatin opening at viral replication compartments facilitates the recruitment of these DNA repair factors to the viral genomes. In other words, the virus appears to use a host remodeling enzyme to prepare its own chromatin so that the damage response can be efficiently installed exactly where it is needed. Without MORC2, the signaling cascade on viral DNA is weakened, and the consequences for viral replication and progeny production follow directly.

Perhaps the most intriguing part of the study concerns how MORC2 is delivered to the viral replication compartments in the first place. The authors found that HCMV UL112-113, a viral locus whose products are known to participate in the early assembly of replication compartments, mediates a process of phase separation that facilitates MORC2 recruitment. Phase separation is a physical phenomenon in which proteins and nucleic acids condense into membrane-less compartments, a mechanism increasingly recognized as a general principle of cellular organization. In the context of HCMV infection, UL112-113-driven condensates appear to concentrate MORC2 within the viral replication compartments, ensuring that the remodeler acts preferentially on viral rather than host chromatin.

This recruitment mechanism ties together several threads of modern virology and cell biology. Large DNA viruses such as HCMV must build dedicated nuclear factories for genome synthesis, and phase-separated condensates have emerged as a structural principle of these factories. The new findings suggest that such condensates do more than concentrate viral replication proteins; they also serve as docking environments for host factors that the virus needs, in this case a chromatin remodeler that tunes the physical state of viral DNA. By coupling condensate formation to the recruitment of MORC2, the virus achieves a degree of selectivity that would otherwise be difficult to explain, given the enormous excess of host chromatin in the infected nucleus.

The broader significance of the work lies in the framework it provides for understanding how DNA viruses cope with replication stress. Rather than encoding its own repair machinery, HCMV appears to have evolved to co-opt host chromatin dynamics, converting a general host stress response into a virus-supportive program. The authors describe this as a mechanistic framework for how DNA viruses alleviate replication stress by hijacking host chromatin remodelers. Because MORC2 is required for efficient viral DNA replication and progeny production, the protein also emerges as a potential point of vulnerability for antiviral intervention, although the study itself is framed as basic mechanistic biology rather than therapeutic development.

For the field of herpesvirus biology, the study adds MORC2 to a growing list of host chromatin-associated factors whose services are enlisted by HCMV, and it connects the viral DNA damage response to the physical organization of replication compartments through phase separation. It also raises questions that future work will need to address, including which specific repair pathways are loaded onto viral genomes downstream of MORC2-mediated chromatin opening, and whether other DNA viruses deploy comparable strategies to remodel their chromatin during infection. What is already clear from the present findings is that the boundary between viral and host genome management is far more permeable than a simple list of viral genes might suggest, and that a 230-kilobase viral genome depends, in part, on the remodeling activities of the very cell it infects.

Subject of Research: How human cytomegalovirus recruits the host chromatin remodeler MORC2 to activate the DNA damage response on viral genomes during lytic infection.

Article Title: Human cytomegalovirus exploits host chromatin remodeler MORC2 to promote the DNA damage response on viral genomes

Article References: Jeong, J., Jeong, D., Lee, S., Park, J., Kim, H., & Ahn, K. (2026). Human cytomegalovirus exploits host chromatin remodeler MORC2 to promote the DNA damage response on viral genomes. PLOS Pathogens, 22(10), e1014693. https://doi.org/10.1371/journal.ppat.1014693

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014693

Keywords: human cytomegalovirus, MORC2, chromatin remodeling, DNA damage response, viral replication compartments, gamma-H2AX, phase separation, UL112-113, herpesvirus, replication stress, PLOS Pathogens, viral chromatin

In research published in Molecular Biology Reports, a team from the Czech Academy of Sciences and the Czech Technical University in Prague exposed MCF-7 breast cancer cells to cobalt-60 gamma radiation across a remarkably wide dose range, from a therapeutic 8 gray down to just 0.1 gray, a hundredfold lower. Using western blotting to track protein levels and real-time quantitative PCR to measure gene expression, they discovered that the p53 system responds to even the faintest doses with a recognizable, if muted, dynamic signature: a transient peak of p53 induction that appears later and weaker than at high doses, but is unmistakably present.

The significance of this finding lies in what classical models predicted. Mathematical descriptions of the p53-MDM2 feedback loop, built on decades of high-dose experiments, suggested that when cellular stress falls below a critical threshold, oscillatory behaviour should vanish entirely. Instead, p53 and MDM2 were expected to rise gently to a steady, lower plateau. The Czech team’s data tell a different story. At 0.25 and 0.1 gray, both proteins still showed transient peaks, reaching upregulation factors of roughly 1.2 to 1.5 between three and six hours after irradiation, followed by decline. The system, it seems, retains its dynamic character even when the initiating signal is feeble.

To appreciate why this matters, it helps to understand the machinery involved. Under normal conditions, p53 is kept at low concentrations by MDM2, an E3 ubiquitin ligase that tags p53 for destruction. The relationship is circular: p53 activates transcription of the MDM2 gene, and the resulting MDM2 protein suppresses p53, forming a classic negative feedback loop. When ionizing radiation shatters DNA, sensor kinases such as ATM phosphorylate both proteins, breaking their embrace and allowing p53 to accumulate in the nucleus, where it switches on hundreds of genes governing cell cycle arrest, DNA repair, senescence, and apoptosis.

Earlier work had established that this loop can generate oscillations. Population-level studies in MCF-7 cells revealed damped pulses of p53 after gamma irradiation, while single-cell imaging showed that individual cells produce nearly undamped pulses of constant amplitude and period, roughly four hours in MCF-7 cells. Intriguingly, the dose did not change the shape of each pulse; instead, higher doses recruited more oscillating cells and extended the total number of pulses. The p53 system, in other words, encodes dose information in duration rather than amplitude, a digital-like strategy that has fascinated systems biologists since it was first described.

What remained unknown was the low-dose frontier, below 1 gray, where radiation protection regimes and diagnostic exposures actually operate. The Prague team, led by Irina Danilova and corresponding author Marie Davídková, irradiated cells in a carefully calibrated water phantom at the Nuclear Physics Institute, using a reduced dose rate of about 0.125 gray per minute for low-dose exposures and verifying positioning errors of under 2 percent. They first confirmed that DNA double-strand breaks were indeed induced across the range by measuring gamma-H2AX, the phosphorylated histone that marks break sites, which rose dose-dependently immediately after exposure and peaked within one to two hours at 8 gray before gradually declining.

At high doses, the results reproduced the canonical picture: p53 peaked around two hours post-irradiation, rising up to threefold, while MDM2 followed with a roughly two-hour delay, climbing as much as eightfold. The p53 target genes CDKN1A, which encodes the cell cycle inhibitor p21, GADD45A, involved in DNA repair, and MDM2 itself all surged up to sixfold at 8 gray, with the maximum shifting later and shrinking as the dose dropped. But the crucial observation came at the bottom of the range. Even at 0.1 gray, all three genes and both proteins displayed transient peaks, with GADD45A mRNA reaching about 1.3-fold upregulation three hours after exposure, albeit with considerable scatter in the data.

To test whether these low-dose responses were qualitatively different from the oscillatory high-dose behaviour, the researchers fitted all their datasets to a damped oscillator model driven by an exponentially decaying damage signal, comparing it against a simple constant response using the Akaike information criterion. In 21 of 25 endpoint-dose combinations, the damped oscillatory model was clearly preferred, including for p53 protein at 0.1 gray. The fitted parameters told a coherent story: response amplitudes grew nearly proportionally with dose, consistent with the linear relationship between radiation dose and DNA breaks, while the onset delay shortened and the damping ratio increased as dose decreased, stretching the oscillation period until the response approached a critically damped, single-peak regime.

The authors are careful to acknowledge the limitations of their analysis. The data span only eight hours, error bars are substantial, as is typical in biological measurements, and the model lumps all endpoints into a single system with one intrinsic frequency, treating the cascade from DNA damage through p53 to its transcriptional targets in a simplified fashion. A few datasets, notably MDM2 and CDKN1A expression at 0.1 gray and MDM2 protein at 0.25 gray, did not clearly favour the oscillatory model, likely because peak amplitudes were too small to resolve. Yet the overall conclusion stands: there is no qualitative switch between high-dose and low-dose p53 dynamics, merely a progressive attenuation and delay.

The implications ripple outward in several directions. For radiation protection, the finding suggests that cellular defence programmes are engaged at doses far below those where overt harm is evident, meaning the biological response to low-dose exposure is not silence but a quiet, attenuated echo of the full alarm. For radiotherapy, understanding how p53 dynamics scale with dose in hormone-dependent tumours like the MCF-7 model could inform strategies that exploit p53-mediated radiosensitivity. And for basic biology, the work challenges modellers to refine their threshold predictions and points toward the next frontier: single-cell fluorescence imaging, ChIP-sequencing, and single-cell RNA sequencing to reveal how individual cells interpret these faint signals. The guardian, it turns out, never fully sleeps; it simply whispers when the danger is small.

Subject of Research: Dose-dependent dynamics of p53 and MDM2 activation in MCF-7 breast cancer cells exposed to low-dose gamma radiation

Article Title: Transient peak of p53 induction persists at low radiation doses in MCF-7 cells

Article References: Danilova, I., Klementová, J., Jarošová, Š., Kundrát, P., Zíková, M., & Davídková, M. (2026). Transient peak of p53 induction persists at low radiation doses in MCF-7 cells. Molecular Biology Reports, 53(1), Article 1668. https://doi.org/10.1007/s11033-026-12787-7

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12787-7

Keywords: p53, MDM2, MCF-7 cells, ionizing radiation, low-dose radiation, DNA damage response, gamma-H2AX, CDKN1A, GADD45A, oscillatory dynamics, breast cancer, radiation biology

The research, led by Kamila Maliszewska-Olejniczak of Warsaw University of Life Sciences together with colleagues at the Nencki Institute of Experimental Biology and the National Centre for Nuclear Research in Poland, examined how deleting the large-conductance calcium-activated potassium channel, known as BKCa, alters the way glioblastoma cells respond to ultra-high dose rate electron irradiation. This irradiation regime is the laboratory cousin of FLASH radiotherapy, an emerging modality that delivers radiation at dose rates exceeding 40 Gy per second in millisecond bursts. Preclinical work has repeatedly suggested that FLASH delivery spares normal tissue while preserving tumor kill, a phenomenon called the FLASH effect, thought to involve transient oxygen depletion and reduced reactive oxygen species chemistry. Yet the underlying biology remains stubbornly unclear, and the new findings suggest that ion channels may be part of the answer.

BKCa channels are not passive bystanders in glioblastoma. They are overexpressed in established cell lines such as U87MG and T98G, in glioblastoma stem-like cells, and in primary cells from patient biopsies, and a glioma-specific splice variant called gBKCa is highly expressed in the disease. These so-called oncochannels support migration and invasion by driving the ion and water efflux needed for cell shrinkage during movement, and they are functionally upregulated under hypoxia, contributing to chemoresistance. Crucially, a mitochondrial isoform, mitoBKCa, helps govern mitochondrial function and oxidative stress, and previous work by the same group showed that its loss elevates mitochondrial reactive oxygen species in U87MG cells. Because ionizing radiation acts largely through oxidative chemistry, the team hypothesized that BKCa deletion might reshape the cellular response to ultra-high dose rate beams.

To test this, the researchers used CRISPR-Cas9 genome editing to generate U87MG cells lacking the pore-forming alpha subunit encoded by KCNMA1, then exposed both wild-type and knockout cells to a 9 MeV electron beam delivered by a modified intraoperative linear accelerator operating in FLASH mode at an average dose rate of 150 Gy per second, with total irradiation times under 40 milliseconds. Doses of approximately 2, 3 and 5 Gy were verified with radiochromic film and a real-time inductive dosimetry system, with flasks positioned in a slab phantom under ambient oxygen conditions. The team then interrogated the cells with a comprehensive battery of assays: clonogenic survival, fluorescence-based ROS measurement, BrdU-DAPI cell-cycle analysis, Annexin V and propidium iodide staining, PARP1 cleavage detection, the alkaline comet assay, gamma-H2AX flow cytometry, 53BP1 immunofluorescence, quantitative PCR for fourteen DNA repair genes, and Western blotting.

The first surprise was what did not change. Clonogenic survival, the gold-standard endpoint of radiobiology, declined dose-dependently in both cell lines, from full survival in untreated controls to roughly 27 percent at 5 Gy in wild-type cells and about 35 percent in knockout cells, but the differences between genotypes were not statistically significant at any dose. Deleting BKCa, in other words, did not make the cells more resistant or more sensitive in terms of long-term colony-forming capacity. Yet beneath this deceptively calm surface, the molecular machinery was behaving very differently. Knockout cells accumulated significantly more reactive oxygen species after 3 Gy, reaching levels of 4.66 relative units compared with 2.21 in wild-type cells, consistent with the idea that the channel helps maintain mitochondrial redox homeostasis and that its absence leaves cells more vulnerable to radiation-induced oxidative stress.

The cell-cycle response also diverged sharply. Thirty minutes after irradiation, wild-type cells distributed themselves across G0/G1, S and G2/M phases, whereas the knockout cells piled up dramatically in G0/G1, reaching nearly 75 percent of the population compared with about 48 percent in irradiated wild-type cells. Notably, the genotoxic chemotherapeutic etoposide produced a classic G2/M arrest in both lines, showing that the two cell lines respond differently to distinct forms of DNA damage and that the G0/G1 accumulation is a specific feature of the ultra-high dose rate response in channel-deficient cells. The authors caution that their data do not establish a direct causal mechanism linking BKCa deletion to this checkpoint redistribution, and that future work on specific checkpoint regulators will be needed.

Cell death signaling told a subtler story. Both cell lines showed reduced viability and increased early apoptosis after irradiation, but without significant differences between genotypes. Cleaved PARP1, a caspase-generated marker of apoptotic signaling, rose significantly in knockout cells but not in wild-type cells, although the between-genotype comparison did not reach significance and Western blotting of the cleaved-to-full-length PARP1 ratio showed no genotype-dependent difference. The most striking finding, however, concerned DNA damage signaling itself. Despite suffering comparable or greater DNA strand damage, as confirmed by the alkaline comet assay with tail DNA rising to more than 80 percent in irradiated knockout cells, the knockout cells accumulated far less gamma-H2AX, the phosphorylated histone that marks double-strand breaks, reaching only about 24 percent positive cells versus nearly 70 percent in irradiated wild-type cells. Formation of 53BP1 foci, which recruit repair complexes to damaged chromatin and bias repair toward non-homologous end joining, was likewise significantly reduced in the knockout cells.

The authors are careful to stress that reduced gamma-H2AX and 53BP1 should not be read as an absence of DNA damage. The comet assay proves the damage is there. Rather, the findings point to impaired damage recognition and altered assembly of repair complexes, a dysregulation of the early DNA damage response rather than a reduction in the insult itself. This interpretation is reinforced by the transcriptional data. Irradiated knockout cells upregulated double-strand break repair genes including ATM, BRCA1 and RAD51 relative to irradiated wild-type cells, while simultaneously downregulating single-strand break repair genes dependent on PARP enzymes, including PARP1, PARP2, PARP3 and XRCC1. The team had previously implicated BKCa as a regulator of the DNA damage response under oxidative stress caused by particulate matter exposure, and the new results extend that concept to ionizing radiation delivered at ultra-high dose rates.

The study has clear limitations that the authors acknowledge candidly. All experiments used a single isogenic U87MG model in vitro, so validation in additional cell lines and patient-derived glioblastoma models is essential, and no conventional dose-rate control was included, meaning the observed effects cannot be attributed specifically to the FLASH effect as opposed to the irradiation conditions used. Nevertheless, the work identifies BKCa as a genuine modulator of the early molecular response of glioblastoma cells to ultra-high dose rate irradiation, spanning redox balance, cell-cycle distribution, DNA damage signaling, apoptotic markers and repair gene transcription. Given that potassium channels can be targeted pharmacologically or genetically, the findings open a plausible path toward combining channel modulation with FLASH radiotherapy and temozolomide, although the authors emphasize that the present data provide no evidence yet of BKCa-dependent radiosensitization. As clinical FLASH trials accelerate, understanding which molecular levers distinguish tumor from normal tissue responses may prove decisive, and this study suggests that an ion channel once studied mainly for its role in cell migration may be one of those levers.

Subject of Research: How BKCa potassium channel deletion modulates the DNA damage response of glioblastoma cells to electron ultra-high dose rate irradiation

Article Title: BKCa channel deletion modulates the DNA damage response to electron ultra-high dose rate irradiation in glioblastoma cells

Article References: Maliszewska-Olejniczak, K., Fryc, M., Kustra, A., Wiktorska, K., Lenartowicz-Gasik, A., Soroka, W., Rzadkiewicz, J., Żochowska, M., Kulawiak, B., & Bednarczyk, P. (2026). BKCa channel deletion modulates the DNA damage response to electron ultra-high dose rate irradiation in glioblastoma cells. Journal of Neuro-Oncology, 179(3), Article 95. https://doi.org/10.1007/s11060-026-05804-z

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05804-z

Keywords: glioblastoma, BKCa channel, FLASH radiotherapy, ultra-high dose rate irradiation, DNA damage response, gamma-H2AX, 53BP1, reactive oxygen species, U87MG cells, apoptosis, DNA repair, ion channels

The researchers, led by Caoimhe Morley and Christos Proukakis, built on their earlier finding that somatic copy number gains of SNCA, the gene encoding alpha-synuclein, occur in the brains of people with synucleinopathies. In their new study, published in Acta Neuropathologica, they asked whether these gains arise specifically in oligodendrocytes, whether they cluster in the brain regions most damaged by the disease, and whether they correlate with the pathological inclusions that define it. Their strategy hinged on a technically demanding hybrid method that combines fluorescent in situ hybridisation, or FISH, with immunofluorescence, applied not to tissue sections but to suspensions of individual nuclei isolated from fresh-frozen post-mortem brain tissue.

The methodological choice matters. Working on sections makes it nearly impossible to reliably detect copy number losses, because slicing the tissue can truncate FISH signals and mimic a missing gene copy. Isolating nuclei eliminates this artefact while preserving alpha-synuclein inclusions, which in multiple system atrophy often sit in perinuclear or nuclear positions and remain attached to the nuclei during preparation. Each nucleus could therefore be interrogated on several axes simultaneously: the number of SNCA copies it carried, whether it belonged to the oligodendrocyte lineage as marked by the transcription factor SOX10, and whether it harboured an alpha-synuclein inclusion. The team analysed tissue from the putamen, cerebellum and substantia nigra of 13 cases with the striatonigral degeneration subtype, 12 cases with the olivopontocerebellar atrophy subtype, and 15 controls from the Queen Square Brain Bank.

The results were striking. Somatic SNCA copy number variants, both gains and losses, were significantly more frequent in multiple system atrophy oligodendrocytes than in controls. Gains were enriched more than threefold, appearing in 6.3 percent of SOX10-positive oligodendrocytes compared with 2.0 percent in controls, while losses were present in 12.5 percent versus 7.4 percent, with both differences highly significant. Crucially, the gains were not randomly distributed. They concentrated in the regions preferentially devastated by each disease subtype: the putamen in striatonigral degeneration and the cerebellum in olivopontocerebellar atrophy, along with the substantia nigra in both. The analysis also showed that CNVs were preferentially enriched at the SNCA locus itself; a chromosome 7 reference probe displayed relative genomic stability, indicating a locus-specific phenomenon rather than wholesale genomic chaos.

The single-cell correlations provide the study’s most provocative evidence. In the preferentially affected region of each subtype, oligodendrocytes carrying a somatic SNCA gain were more than twice as likely to contain an alpha-synuclein inclusion as their neighbours with a normal copy number, an effect that vanished in less affected regions. At the regional level, the frequency of oligodendrocyte gains correlated significantly with the overall burden of glial inclusions. This dovetails with established biology: people who inherit extra copies of SNCA develop parkinsonism driven by chronic alpha-synuclein overproduction, with duplications causing later-onset disease and triplications causing aggressive early-onset forms. Mouse models engineered to overexpress human alpha-synuclein specifically in oligodendrocytes develop inclusion-like pathology, demyelination and neuroinflammation. The new data suggest that the same dosage logic operates cell by cell in the human disease brain, with gains locally pushing intracellular alpha-synuclein toward the aggregation threshold.

Perhaps the most clinically resonant finding is a correlation between copy number gain burden and disease onset. Cases carrying a higher average proportion of oligodendrocyte SNCA gains developed symptoms significantly earlier, with a Spearman correlation coefficient of minus 0.45 and a p-value of 0.03. No such relationship existed for gains in non-oligodendroglial cells or for losses. Moreover, within individual cases, the level of gains correlated across brain regions and between oligodendrocytes and other cell populations, hinting that some patients carry an intrinsic, case-wide propensity for SNCA mosaicism. This raises the possibility of an early clonal event, arising during development, that seeds descendant cells across multiple regions and predisposes the brain to alpha-synuclein aggregation decades later. Distinguishing this from a generalised susceptibility to SNCA instability will require deep single-cell whole-genome sequencing, which is only now approaching the necessary resolution.

The study also reported, for the first time in multiple system atrophy, somatic SNCA losses. These were elevated in both oligodendrocytes and other cells but told a different story. They showed no clear regional predilection matching each subtype’s pathology, associated with inclusions only in the substantia nigra, and showed no correlation with age of onset or disease duration. That pattern argues against a primary causal role. Unlike gains, germline losses of SNCA have never been linked to synucleinopathies, and mice lacking alpha-synuclein do not develop relevant neurodegenerative phenotypes. The authors instead propose that losses may arise secondarily as the disease progresses, through the mis-repair of DNA damage.

That hypothesis gains weight from the study’s final arm, an examination of DNA double-strand breaks using immunofluorescence for gamma H2AX, the phosphorylated histone that marks sites of breakage and repair. Across the sampled regions, the proportion of gamma H2AX-positive cells was significantly higher in multiple system atrophy than in controls, 4.9 versus 2.5 percent overall, and nearly fourfold higher within oligodendrocytes. The signal was stronger in the preferentially affected regions and, strikingly, present in 22.2 percent of inclusion-bearing cells versus 14.9 percent of inclusion-free ones. This mirrors recent reports in Lewy body diseases linking DNA damage to alpha-synuclein pathology. Because post-mitotic brain cells repair double-strand breaks through the error-prone non-homologous end joining pathway, unrepaired or mis-repaired breaks can generate deletions, potentially including SNCA itself. Yet the authors caution that more than three-quarters of inclusion-positive cells showed no evidence of breaks, and the temporal sequence of damage, aggregation and copy number change remains unresolved.

The findings do not paint copy number variation as a sole cause. Most inclusion-bearing oligodendrocytes carried a normal SNCA copy number, and individuals with inherited SNCA multiplications typically develop a Parkinson-like picture rather than full multiple system atrophy, suggesting that somatic gains act as one influential contributor among many, a first hit or modifier that lowers the threshold for aggregation within vulnerable glia. Cell-type-specific stress, environmental exposures, unidentified inherited variants and other somatic mutations, possibly including age-related clonal haematopoiesis recently associated with the disease, are likely to complete the picture. Even so, the work reframes the search for multiple system atrophy’s origins. The culprit may not lie in the genome everyone inherits, but in the mosaic of genomes that individual brain cells acquire across a lifetime, and in oligodendrocytes silently accumulating extra copies of the very gene whose protein will one day fill them with inclusions.

Subject of Research: Somatic SNCA copy number variation in oligodendrocytes and its role in multiple system atrophy pathogenesis

Article Title: Oligodendroglial somatic SNCA copy number gains are associated with inclusions and disease onset in multiple system atrophy

Article References: Morley, C., Kalef-Ezra, E., Perez-Rodriguez, D., Jaunmuktane, Z., & Proukakis, C. (2026). Oligodendroglial somatic SNCA copy number gains are associated with inclusions and disease onset in multiple system atrophy. Acta Neuropathologica, 152(1), Article 31. https://doi.org/10.1007/s00401-026-03077-4

Image Credits: AI Generated

DOI: 10.1007/s00401-026-03077-4

Keywords: multiple system atrophy, SNCA, alpha-synuclein, oligodendrocytes, somatic copy number variants, glial cytoplasmic inclusions, DNA double-strand breaks, gamma H2AX, fluorescent in situ hybridisation, genetic mosaicism, synucleinopathy, neurodegeneration